别名 Alpha-ENaC、Alpha-ENaC","ENaCA、Alpha-NaCH + [10] |
简介 Sodium permeable non-voltage-sensitive ion channel inhibited by the diuretic amiloride. Mediates the electrodiffusion of the luminal sodium (and water, which follows osmotically) through the apical membrane of epithelial cells. Plays an essential role in electrolyte and blood pressure homeostasis, but also in airway surface liquid homeostasis, which is important for proper clearance of mucus. Controls the reabsorption of sodium in kidney, colon, lung and eccrine sweat glands. Also plays a role in taste perception. |
靶点 |
作用机制 ENaCα抑制剂 |
在研机构 |
原研机构 |
非在研适应症- |
最高研发阶段批准上市 |
首次获批国家/地区 美国 |
首次获批日期1981-10-05 |
作用机制 ENaCα抑制剂 [+2] |
在研适应症 |
非在研适应症 |
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
靶点 |
作用机制 ENaCα抑制剂 |
非在研适应症- |
最高研发阶段临床阶段不明 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
开始日期2023-08-10 |
申办/合作机构 Yale University [+1] |
开始日期2021-10-01 |
申办/合作机构 |
开始日期2020-11-16 |
申办/合作机构 |